1.	Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0401, NCT00602030
2.	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01077, E1905, U10CA021115, ECOG-E1905, NCT00313586
3.	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00195, J06114, U01CA070095, JHOC-J06114, 7605, NA_00006989, NCT00462605
4.	Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0301, NCT00676663
5.	A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0403, NCT00750698
6.	A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing Phase: Phase II Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0303, NCT00828854
7.	A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0501, NCT00866333
8.	Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2010-02024, MC084B, N01CM62209, N01CM62205, CDR0000670136, MAYO-MC084B, 8341, NCT01105377
9.	Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02542, 10-466-A, N01CM00071, UCCRC-IL-057, IL-057, 8597, NCT01234532
10.	MS-275 in Treating Patients With Hematologic Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068574, J0253, U01CA069854, P30CA006973, JHOC-J0253, MSGCC-0050, NCI-2791, NCT00015925
11.	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02634, JHOC-J0438, U01CA070095, CDR0000396776, 6798, NCI-6798, JHOC-04060103, NCT00098891
12.	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00071, J0443, CDR0000405841, U01CA070095, JHOC-J0443, NCI-6591, JHOC-04061109, 6591, NCT00101179
13.	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01435, I-165409, CDR0000675600, RPCI-I-165409, 8272, NCT01159301
14.	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, NIH WGMCC Protocol IDs: 010124, 01-C-0124, NCI-2792, CDR0000068615, NCI-01-C-0124, 2792, NCT00020579